



Xofigo (radium-223 dichloride) Solution for injection	
Indication	Xofigo is used to treat adult men with cancer of the prostate when medical or surgical castration does not work, and when the cancer has spread to the bones and is causing symptoms.
Reason for shortage	In September 2014, some batches of Xofigo did not pass routine quality checks and were not released, causing a temporary shortage of the medicine. In order to maintain supply, batches were subsequently released after additional visual checks and removal of affected vials. As an additional precaution, Xofigo product from these batches had to be filtered before use. The causes of the quality problems have now been addressed by the company and filtration before use is no longer required.
Member States affected	All EU Member States where Xofigo was previously available.
Information to healthcare professionals	<ul style="list-style-type: none">• Letters from the company have been sent out to healthcare professionals informing them that the problems have been addressed and normal production has resumed.• Xofigo should no longer be filtered before administration and the shortage situation is resolved.• Additional advice may be available from the national competent authority.
Information to patients	<ul style="list-style-type: none">• Problems with the supply of Xofigo have now been resolved.• The clinic should not filter Xofigo before giving it to a patient.• Patients who have any questions should speak to their doctor.• Additional advice may be available from the national competent authority.
Status	Resolved
Date of publication	28 April 2015

